# IRulya Therapeutics Inc. (IRLA) fundamentals

Data as of 2026-11-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $31.00, market value $336 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). IRulya Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Free-cash-flow yield: -14.0%** (5-yr avg -1.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 235.1%**. A 235.1% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.

## Growth
- **EPS growth (1 yr): -28.2%**. Earnings per share fell 28.2%.

## Financial health
- **Current ratio: 0.53** (quick 0.53). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. IRulya Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -90.3%** (YTD -95.4%, 3-mo 2.6%). The shares are down 90.3% over twelve months including dividends.
- **From 52-week high: -96.6%** (105.3% above the low). Trading 97% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 1.78** (volatility 357%). Beta of 1.78 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IRLA · Page: https://foliofundamentals.com/stocks/irla

Not investment advice.